amifostine anhydrous and mannitol

amifostine anhydrous has been researched along with mannitol in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (14.29)	18.7374
1990's	3 (42.86)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (42.86)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Boven, E; Holwerda, U; Pinedo, HM; Treskes, M; van der Vijgh, WJ	1
Cannon, L; Fox, K; Glick, J; Glover, D; Grabelsky, S; Weiler, C	1
Anand, AJ; Bashey, B	1
Schacht, J; Song, BB	1
Akbulut, S; Bayraktar, N; Dagdeviren, A; Karakayali, H; Oksuz, E; Sevmis, S; Unlukaplan, M	1

Reviews

2 review(s) available for amifostine anhydrous and mannitol

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Newer insights into cisplatin nephrotoxicity. The Annals of pharmacotherapy, 1993, Volume: 27, Issue:12 Topics: Amifostine; Animals; Cisplatin; Furosemide; Glutathione; Humans; Kidney Diseases; Male; Mannitol; Sodium Chloride; Thiosulfates	1993

Trials

1 trial(s) available for amifostine anhydrous and mannitol

Article	Year
Clinical trials of WR-2721 and cis-platinum. International journal of radiation oncology, biology, physics, 1989, Volume: 16, Issue:5 Topics: Adult; Aged; Amifostine; Cisplatin; Diuresis; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Mannitol; Middle Aged; Neoplasms; Organothiophosphorus Compounds	1989

Other Studies

4 other study(ies) available for amifostine anhydrous and mannitol

Article	Year
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer research, 1992, Apr-15, Volume: 52, Issue:8 Topics: Amifostine; Animals; Cisplatin; Drug Administration Schedule; Female; Kidney; Liver; Male; Mannitol; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Premedication; Time Factors; Tumor Cells, Cultured; Urea	1992
Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo. Hearing research, 1996, Volume: 94, Issue:1-2 Topics: Administration, Oral; Allopurinol; Amifostine; Analysis of Variance; Animals; Anti-Bacterial Agents; Antimetabolites; Antioxidants; Auditory Threshold; Benzoates; Deferoxamine; Dimethyl Sulfoxide; Free Radical Scavengers; Gentamicins; Guinea Pigs; Hydroxybenzoates; Injections, Intraperitoneal; Injections, Subcutaneous; Iron; Iron Chelating Agents; Male; Mannitol; Pregnatrienes	1996
Amifostine enhances the antioxidant and hepatoprotective effects of UW and HTK preservation solutions. World journal of gastroenterology, 2014, Sep-14, Volume: 20, Issue:34 Topics: Adenosine; Alanine Transaminase; Alkaline Phosphatase; Allopurinol; Amifostine; Animals; Antioxidants; Apoptosis; Biomarkers; Biopsy; Cold Ischemia; Cytoprotection; Drug Synergism; Glucose; Glutathione; Hepatectomy; In Situ Nick-End Labeling; Insulin; Liver; Male; Mannitol; Microscopy, Electron, Transmission; Models, Animal; Nitric Oxide; Nitric Oxide Synthase Type II; Organ Preservation; Organ Preservation Solutions; Potassium Chloride; Procaine; Raffinose; Rats, Sprague-Dawley; Time Factors	2014